Fighting back against chikungunya

Chikungunya is a mosquito-borne disease that leaves the afflicted patient with incapacitating arthritis that can last for several months or even years.1 Since the start of the largest ever outbreak of chikungunya virus infecton in 2005 in the Indian Ocean, there has been a resurgence in chikungunya...

Full description

Saved in:
Bibliographic Details
Published inThe Lancet infectious diseases Vol. 15; no. 5; pp. 488 - 489
Main Authors Rudd, Penny A, Mahalingam, Suresh
Format Journal Article
LanguageEnglish
Published United States Elsevier Ltd 01.05.2015
Elsevier Limited
Subjects
Antibodies, Neutralizing - blood
Antibodies, Viral - blood
Antigens, Viral - administration & dosage
Aquatic insects
Candidates
Chikungunya Fever - prevention & control
Chikungunya virus - immunology
Comment
Female
Humans
Infectious Disease
Infectious diseases
Male
Measles
Measles virus - immunology
Medical research
Mosquitoes
Pain
Vaccines
Vector-borne diseases
Viral Vaccines - administration & dosage
Online AccessGet full text

Cover

More Information
Summary:Chikungunya is a mosquito-borne disease that leaves the afflicted patient with incapacitating arthritis that can last for several months or even years.1 Since the start of the largest ever outbreak of chikungunya virus infecton in 2005 in the Indian Ocean, there has been a resurgence in chikungunya cases that continues to this day.1 Adaptation of chikungunya virus to the globally distributed Asian tiger mosquito (Aedes albopictus) has led to autochthonous cases in both Europe and the Americas.2 In the year after chikungunya virus first appeared in the Caribbean, an estimated 1 million cases were reported, with concerns that the virus could spread extensively throughout the Americas.3 Despite the emerging importance of chikungunya virus, no specific treatment or vaccine is available for infected individuals. Several other vaccine candidates and strategies that have yielded promising preclinical data, such as use of the picornavirus internal ribosome entry site or subunit, genetic, or recombinant modified vaccinia virus Ankara-based vaccines.14,15 The road towards development of a vaccine approved by the US Food and Drug Administration is long and winding, but with two potential candidates in the pipeline, we might be on the right track in the fight against chikungunya.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Commentary-1
ObjectType-Article-1
ObjectType-Feature-2
ISSN:1473-3099
1474-4457
DOI:10.1016/S1473-3099(15)70079-4